Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease

Author:

Chuang Wan-Long,Hu Tsung-Hui,Buggisch Peter,Moreno Christophe,Su Wei-Wen,Biancone Luigi,Camargo Marianne,Hyland Robert,Lu Sophia,Kirby Brian J.,Dvory-Sobol Hadas,Osinusi Anu,Gaggar Anuj,Peng Cheng-Yuan,Liu Chen-Hua,Sise Meghan E.,Mangia Alessandra

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference11 articles.

1. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection;Park;J Viral Hepat,2015

2. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies;Fabrizi;J Viral Hepat,2007

3. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting;Beinhardt;Transpl Int,2016

4. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure;Dumortier;Nephrol Dial Transpl,2017

5. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function;Saxena;Liver Int,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3